Oxybutinin - linked to Dementia - our response
3 April, 2017
STATEMENT IN RESPONSE TO DAILY MAIL ARTICLE ON TUESDAY, 28TH MARCH
Bladder Health UK is aware of an article which appeared in the Daily Mail on Tuesday, 28th March regarding the anticholinergic drug Oxybutinin.
The article is based on a study from the University of Washington in which over 3000 elderly patients with no evidence of dementia were followed for at least seven years. In that time 23% of subjects developed dementia. They found a clear link between the duration of anticholinergic use and the risk of developing dementia but only for those who had taken the medication for more than three years. The authors of the study point out that there is no evidence that anticholinergic medication actually causes dementia and it should also be noted that a 2011 study from the UK, involving 224 patients with existing Alzheimers Disease showed that the use of anticholinergic medication had no impact on cognitive function.
We consulted our medical panel and for those members who are concerned about their use of anticholinergic medication, we suggest that they speak to their consultant/GP. Most anticholinergic drugs can cross into the brain, however Trospium (Regurin ®) does not because of its chemical structure. Mirabegron (Betmiga ®)is a beta-3 agonist and this would also be an option for those who no longer wish to use anticholinergics.
To read the Daily Mail article please click here